Topical proteasome inhibitor promising for rosacea treatment

Topical ACU-D1 was safe, well tolerated and efficacious in treating rosacea, according to a phase 2a study published in the Journal of Drugs in Dermatology. ACU-D1 (pentaerythritol tetrakis (3-(3, 5-di-tert-butyl-4-hydroxyphenyl) propionate), a novel topical proteasome inhibitor, was compared with vehicle in the two-center, randomized, double-blinded, 14-week trial.

“Rosacea is a common disorder of unknown origin, but a distinct pathophysiology,” J. Mark Jackson, MD, of the division of dermatology at University of Louisville, and colleagues wrote. “The study was designed to determine whether topical ACU-D1 is safe and effective in patients and whether there were any adverse effects from active or vehicle.”